CERS6 and obesity due to melanocortin 4 receptor deficiency: Targeting CerS6-dependent ceramide synthesis in the hypothalamus holds promise for obesity and diabetes therapies, offering potential advantages over complete inhibition of sphingolipid/ceramide synthesis with reduced side effects.